Case Study: Inhibitors of the MDM2‐p53 Protein–Protein Interaction

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Unknown venue

• Publication date

  2010-11-30

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1002/9780470972137.CH10
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer

  2008cited by this paper
• Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

  2008cited by this paper
• Inhibition of the p53 E3 Ligase HDM-2 Induces Apoptosis and DNA Damage–Independent p53 Phosphorylation in Mantle Cell Lymphoma

  2008cited by this paper
• Targeting the MDM2-p53 Interaction for Cancer Therapy

  2008cited by this paper
• Targeting protein-protein interactions: lessons from p53/MDM2.

  2007cited by this paper
• Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.

  2007cited by this paper
• Cyclin-Dependent Kinase Inhibitors Sensitize Tumor Cells to Nutlin-Induced Apoptosis: a Potent Drug Combination

  2007cited by this paper
• Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

  2007cited by this paper
• Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3

  2007cited by this paper
• Restoration of p53 function leads to tumour regression in vivo

  2007cited by this paper
• Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models.

  2007cited by this paper
• Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.

  2007cited by this paper
• MDM2 inhibitors for cancer therapy.

  2007cited by this paper
• MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.

  2006cited by this paper
• Modeling the therapeutic efficacy of p53 restoration in tumors.

  2006cited by this paper
• Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.

  2006cited by this paper
• MDMX Overexpression Prevents p53 Activation by the MDM2 Inhibitor Nutlin*

  2006cited by this paper
• Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.

  2006cited by this paper
• Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).

  2006cited by this paper
• Inactivation of the p53 pathway in retinoblastoma

  2006cited by this paper
• Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.

  2006cited by this paper
• Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.

  2006cited by this paper
• Hdmx Modulates the Outcome of P53 Activation in Human Tumor Cells*

  2006cited by this paper
• Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.

  2006cited by this paper
• Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo

  2006cited by this paper
• Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding.

  2005cited by this paper
• Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma.

  2005cited by this paper
• p53 α-Helix mimetics antagonize p53/MDM2 interaction and activate p53

  2005cited by this paper
• MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy.

  2005cited by this paper
• MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.

  2005cited by this paper
• Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells.

  2005cited by this paper
• 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR.

  2005cited by this paper
• Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction.

  2005cited by this paper
• MDM2 is a central node in the p53 pathway: 12 years and counting.

  2005cited by this paper
• Targeting protein–protein interactions for cancer therapy

  2005cited by this paper
• Structure-based design of potent non-peptide MDM2 inhibitors.

  2005cited by this paper
• In vitro drug resistance in B cell chronic lymphocytic leukemia: a comparison with acute myelocytic and acute lymphocytic leukemia

  2005cited by this paper
• In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

  2004cited by this paper
• Phosphorylation of p53 on Key Serines Is Dispensable for Transcriptional Activation and Apoptosis*♦

  2004cited by this paper
• Mutational spectrum of p53 mutations in primary breast and ovarian tumors.

  2004cited by this paper
• A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

  2004cited by this paper
• A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells.

  2004cited by this paper
• Flexible lid to the p53-binding domain of human Mdm2: Implications for p53 regulation

  2003cited by this paper
• Improved protein–ligand docking using GOLD

  2003cited by this paper
• Control of apoptosis by p53

  2003cited by this paper
• Inhibiting the p53–MDM2 interaction: an important target for cancer therapy

  2003cited by this paper
• Live or let die: the cell's response to p53

  2002cited by this paper
• Further development and validation of empirical scoring functions for structure-based binding affinity prediction

  2002cited by this paper
• Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.

  2001cited by this paper
• Comparison of the NCI Open Database with Seven Large Chemical Structural Databases

  2001cited by this paper
• Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia

  2000cited by this paper
• MDM2--master regulator of the p53 tumor suppressor protein.

  2000cited by this paper
• Mdm2 Gene Amplification in Gastric Cancer Correlation with Expression of Mdm2 Protein and p53 Alterations

  2000cited by this paper
• p53 and human cancer: the first ten thousand mutations.

  2000cited by this paper
• A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.

  2000cited by this paper
• Surfing the p53 network

  2000cited by this paper
• Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53.

  2000cited by this paper
• MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis

  2000cited by this paper
• Functions of the MDM2 oncoprotein

  1999cited by this paper
• Mdm2: The Ups and Downs

  1999cited by this paper
• The MDM2 gene amplification database.

  1998cited by this paper
• Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells

  1998cited by this paper
• Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes

  1997cited by this paper
• Development and validation of a genetic algorithm for flexible docking.

  1997cited by this paper
• Regulation and Significance of Apoptosis in the Stem Cells of the Gastrointestinal Epithelium

  1997cited by this paper
• Identification of novel mdm2 binding peptides by phage display.

  1996cited by this paper
• Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

  1996cited by this paper
• Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

  1995cited by this paper
• Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

  1995cited by this paper
• Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides.

  1994cited by this paper
• National Cancer Institute Drug Information System 3D Database

  1994cited by this paper
• Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.

  1994cited by this paper
• p53 is required for radiation-induced apoptosis in mouse thymocytes

  1993cited by this paper
• Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors.

  1993cited by this paper
• Mapping of the p53 and mdm-2 interaction domains.

  1993cited by this paper
• The p53-mdm-2 autoregulatory feedback loop.

  1993cited by this paper
• The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

  1992cited by this paper
• Amplification of a gene encoding a p53-associated protein in human sarcomas

  1992cited by this paper
• Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.

  1991cited by this paper
• Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells.

  1979cited by this paper
• Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse.

  1979cited by this paper
• T antigen is bound to a host protein in SY40-transformed cells

  1979cited by this paper

• No citing papers are available for this paper.